Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthieu Delaye

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
Bulletin Du Cancer|December 18, 2022
[One year of marketing authorizations in the Bulletin du Cancer, a look back on the year 2022]Matthieu Delaye, Manuel Rodrigues
Bulletin Du Cancer|October 9, 2025
[Nivolumab in combination with ipilimumab - First-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma]Eléa Janvier, Matthieu Delaye
Bulletin Du Cancer|November 10, 2020
[Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion]Matthieu Delaye, Manuel Rodrigues
Bulletin Du Cancer|May 1, 2021
[New European approvals: Pemigatinib - cholangiocarcinoma with a FGFR2 fusion or rearrangement]Matthieu Delaye, Simon Pernot
Bulletin Du Cancer|April 6, 2021
[Learning oncology during the COVID-19 pandemic]Matthieu Delaye, Natacha Naoun
The Lancet. Oncology|September 13, 2025
Neoadjuvant approaches in non-metastatic pancreatic cancer: where do we stand?Matthieu Delaye, Cindy Neuzillet
Bulletin Du Cancer|October 22, 2021
[The AMMs review, assessment after one year of existence]Matthieu Delaye, Manuel Rodrigues
Bulletin Du Cancer|December 16, 2025
[Zanidatamab in second line setting of advanced HER2-positive biliary tract cancers]Ingrid Diagne, Matthieu Delaye
Bulletin Du Cancer|March 1, 2021
[New drug approval: Olaparib and niraparib - first line in ovarian cancer]Matthieu Delaye, Manuel Rodrigues
Bulletin Du Cancer|April 7, 2025
[Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma]Coralie Prevost, Matthieu Delaye
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
Bulletin Du Cancer|December 18, 2022
[One year of marketing authorizations in the Bulletin du Cancer, a look back on the year 2022]Matthieu Delaye, Manuel Rodrigues
Bulletin Du Cancer|October 9, 2025
[Nivolumab in combination with ipilimumab - First-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma]Eléa Janvier, Matthieu Delaye
Bulletin Du Cancer|November 10, 2020
[Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion]Matthieu Delaye, Manuel Rodrigues
Bulletin Du Cancer|May 1, 2021
[New European approvals: Pemigatinib - cholangiocarcinoma with a FGFR2 fusion or rearrangement]Matthieu Delaye, Simon Pernot
Bulletin Du Cancer|April 6, 2021
[Learning oncology during the COVID-19 pandemic]Matthieu Delaye, Natacha Naoun
The Lancet. Oncology|September 13, 2025
Neoadjuvant approaches in non-metastatic pancreatic cancer: where do we stand?Matthieu Delaye, Cindy Neuzillet
Bulletin Du Cancer|October 22, 2021
[The AMMs review, assessment after one year of existence]Matthieu Delaye, Manuel Rodrigues
Bulletin Du Cancer|December 16, 2025
[Zanidatamab in second line setting of advanced HER2-positive biliary tract cancers]Ingrid Diagne, Matthieu Delaye
Bulletin Du Cancer|March 1, 2021
[New drug approval: Olaparib and niraparib - first line in ovarian cancer]Matthieu Delaye, Manuel Rodrigues
Bulletin Du Cancer|April 7, 2025
[Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma]Coralie Prevost, Matthieu Delaye
Pageof 7